The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

A pair of investor calls on Jan. 22 added clarity to the rapidly evolving cardiac ablation market with Abbott Laboratories and Johnson & Johnson providing updates on their pulsed field ablation ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson ...

Johnson & Johnson is like the Fort Knox of dividend stocks. The healthcare company has an AAA bond rating. That's tied for ...

Good morning, and welcome to Johnson & Johnson's fourth-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded. (Operator Instructions) I'd now like to turn the ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...